Rana Said
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Rana Said has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Mohamed Abdel-Rehim
Functional Materials Division, Department of Applied Physics, School of Engineering Sciences KTH Royal Institute of Technology Stockholm Sweden
5 shared publications Anton Pohanka
3 shared publicationsBasel Arafat
Faculty of Health, Education, Medicine, and Social Care, Anglia Ruskin University, Cambridge, UK
3 shared publications- Olof Beck
Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
3 shared publications Tawfiq Arafat
Jordan Center for Pharmaceutical Research (JCPR), Amman, Jordan
3 shared publications- Afnan Al-Hunaiti
Department of Chemistry, University of Jordan, Amman 11942, Jordan
2 shared publications
Latest Publications
- 11 November 2025
- Published by Springer Nature in Transition Metal Chemistry
- Vol. 51 (1) , 1-26
Magnetically recoverable catalysts in aminocarbonylation reactions: a sustainable strategy for synthesis of amides
- 11 November 2025
- Published by Springer Nature in Transition Metal Chemistry
- Vol. 51 (1) , 1-26
Magnetically recoverable catalysts in aminocarbonylation reactions: a sustainable strategy for synthesis of amides
- 5 December 2024
- Published by Elsevier in Current Pharmaceutical Analysis
- Vol. 20 (9) , 978-993
A Bioanalytical Method Using High-performance Liquid Chromatography-mass Spectrometry for Determining Empagliflozin and Linagliptin in Human Plasma: Application in Bioequivalence Pharmacokinetic Study
Background and Objective: A combination of empagliflozin and linagliptin in a fixed dosage was employed for treating individuals with a diagnosis of type 2 diabetes mellitus. A rapid, accurate, and sensitive liquid chromatography-tandem mass spectrometry method was devised and validated for simultaneous measuring empagliflozin and linagliptin levels in human plasma. This method provides a good analytical tool for bioequivalence and pharmacokinetic studies. Methods: The separation was conducted employing a C8 column using a mobile phase consisting of acetonitrile (ACN, 2.5mM) and ammonium chloride (55:45). Optimal detection of the analytes and their deuterated internal standards was accomplished through electrospray ionization in the positive mode. Results: Validation of standard curve concentrations linearity was carried out within the ranges of 1.500 – 500.000 ng/mL for empagliflozin and 0.050 – 7.000 ng/mL for linagliptin. Both drugs showed intra-batch and inter-batch precision (CV%) of less than 3.7%. The stability of the drugs was confirmed under various storage conditions, proving suitability for routine laboratory analysis. Conclusion: This validated method is appropriate for pharmacokinetic studies and large-scale analysis with high precision and accuracy.
- 5 December 2024
- Published by Elsevier in Current Pharmaceutical Analysis
- Vol. 20 (9) , 978-993
A Bioanalytical Method Using High-performance Liquid Chromatography-mass Spectrometry for Determining Empagliflozin and Linagliptin in Human Plasma: Application in Bioequivalence Pharmacokinetic Study
Background and Objective: A combination of empagliflozin and linagliptin in a fixed dosage was employed for treating individuals with a diagnosis of type 2 diabetes mellitus. A rapid, accurate, and sensitive liquid chromatography-tandem mass spectrometry method was devised and validated for simultaneous measuring empagliflozin and linagliptin levels in human plasma. This method provides a good analytical tool for bioequivalence and pharmacokinetic studies. Methods: The separation was conducted employing a C8 column using a mobile phase consisting of acetonitrile (ACN, 2.5mM) and ammonium chloride (55:45). Optimal detection of the analytes and their deuterated internal standards was accomplished through electrospray ionization in the positive mode. Results: Validation of standard curve concentrations linearity was carried out within the ranges of 1.500 – 500.000 ng/mL for empagliflozin and 0.050 – 7.000 ng/mL for linagliptin. Both drugs showed intra-batch and inter-batch precision (CV%) of less than 3.7%. The stability of the drugs was confirmed under various storage conditions, proving suitability for routine laboratory analysis. Conclusion: This validated method is appropriate for pharmacokinetic studies and large-scale analysis with high precision and accuracy.
- 26 November 2024
- Published by Taylor & Francis in Bioanalysis
- Vol. 16 (23-24) , 1261-1278
Iron oxide nanozymes as versatile analytical tools: an overview of their application as detection technique
Iron oxide nanozymes (IONzymes) have become fundamental components in various analyte detection methodologies such as colorimetric, electrochemistry, fluorescence and luminescence. Their tunability, stability and the possibility of modification, alongside their ability to mimic the catalytic properties of natural enzymes like peroxidase, render them invaluable in analytical chemistry. This review explores the diverse applications of IONzymes across analytical chemistry, with a particular highlighting on their roles in different detection techniques and their potential in biomedical and diagnostic applications. This information would be valuable for researchers and practitioners in the fields of analytical chemistry, biochemistry, biotechnology and materials science who are interested in applying IONzymes in their work. In essence, this review article on iron oxide nanozymes in analytical chemistry would serve as a valuable resource for researchers, educators and industry professionals, offering insights, guidance and inspiration for further study and application of this promising class of nanomaterials.
- 26 November 2024
- Published by Taylor & Francis in Bioanalysis
- Vol. 16 (23-24) , 1261-1278
Iron oxide nanozymes as versatile analytical tools: an overview of their application as detection technique
Iron oxide nanozymes (IONzymes) have become fundamental components in various analyte detection methodologies such as colorimetric, electrochemistry, fluorescence and luminescence. Their tunability, stability and the possibility of modification, alongside their ability to mimic the catalytic properties of natural enzymes like peroxidase, render them invaluable in analytical chemistry. This review explores the diverse applications of IONzymes across analytical chemistry, with a particular highlighting on their roles in different detection techniques and their potential in biomedical and diagnostic applications. This information would be valuable for researchers and practitioners in the fields of analytical chemistry, biochemistry, biotechnology and materials science who are interested in applying IONzymes in their work. In essence, this review article on iron oxide nanozymes in analytical chemistry would serve as a valuable resource for researchers, educators and industry professionals, offering insights, guidance and inspiration for further study and application of this promising class of nanomaterials.
- 15 June 2024
- Published by Elsevier in Journal of Chromatography B
- Vol. 1243, 124190
Quantitation of thiorphan in human plasma using LC-MS/MS and its application to a bioequivalence study
- 15 June 2024
- Published by Elsevier in Journal of Chromatography B
- Vol. 1243, 124190
Quantitation of thiorphan in human plasma using LC-MS/MS and its application to a bioequivalence study
- Open Access
- 19 February 2024
- Published by Royal Society of Chemistry (RSC) in Nanoscale Advances
- Vol. 6 (6) , 1611-1642
Magnetic iron oxide-based nanozymes: from synthesis to application
Iron oxide nanozymes, which are magnetic nanoparticles with enzymatic properties, are explored, including their robust production techniques and diverse applications in the fields of biomedicine and environmental science.
- 19 February 2024
- Published by Royal Society of Chemistry (RSC) in Nanoscale Advances
- Vol. 6 (6) , 1611-1642
Open AccessMagnetic iron oxide-based nanozymes: from synthesis to application
Iron oxide nanozymes, which are magnetic nanoparticles with enzymatic properties, are explored, including their robust production techniques and diverse applications in the fields of biomedicine and environmental science.
- 4 November 2022
- Published by Elsevier in Current Pharmaceutical Analysis
- Vol. 19 (2) , 163-175
LC-MS/MS Analytical Method for Determination of Montelukast in Human Plasma and its Application to a Bioequivalence Study
Background: This study aimed to develop a sensitive, rapid method based on HPLC-MS/MS for the quantification of Montelukast in human plasma utilizing Montelukast-D6 as an internal standard. Montelukast is a leukotriene inhibitor and is used to prevent asthma attacks in adults and children. Method: Separation was achieved using Thermo Hypersil GOLD™ Cyano HPLC columns (50 × 4.6 mm; 5 μm) with a mobile phase consisting of 0.5 mM ammonium chloride: ACN (20:80%; v/v). Results: The method was found to be linear over a concentration range of 10.0 - 600.0 ng/mL with a correlation coefficient (r2) ≥ 0. 0.9989. The stabilities of Montelukast and internal standard were assessed in several conditions with recovery results > 85%. The precision results were less than 4.0%, while the accuracy results were within 93.0 107.0%. The method proved to be selective with no matrix effect. Conclusion: This method was found to be highly reproducible and was utilized successfully for the analysis of plasma samples following the oral administration of Montelukast (10 mg) in 28 healthy male human volunteers.
- 4 November 2022
- Published by Elsevier in Current Pharmaceutical Analysis
- Vol. 19 (2) , 163-175
LC-MS/MS Analytical Method for Determination of Montelukast in Human Plasma and its Application to a Bioequivalence Study
Background: This study aimed to develop a sensitive, rapid method based on HPLC-MS/MS for the quantification of Montelukast in human plasma utilizing Montelukast-D6 as an internal standard. Montelukast is a leukotriene inhibitor and is used to prevent asthma attacks in adults and children. Method: Separation was achieved using Thermo Hypersil GOLD™ Cyano HPLC columns (50 × 4.6 mm; 5 μm) with a mobile phase consisting of 0.5 mM ammonium chloride: ACN (20:80%; v/v). Results: The method was found to be linear over a concentration range of 10.0 - 600.0 ng/mL with a correlation coefficient (r2) ≥ 0. 0.9989. The stabilities of Montelukast and internal standard were assessed in several conditions with recovery results > 85%. The precision results were less than 4.0%, while the accuracy results were within 93.0 107.0%. The method proved to be selective with no matrix effect. Conclusion: This method was found to be highly reproducible and was utilized successfully for the analysis of plasma samples following the oral administration of Montelukast (10 mg) in 28 healthy male human volunteers.
- 25 January 2021
- Published by Elsevier in Current Pharmaceutical Analysis
- Vol. 17 (2) , 241-253
An LC-MS/MS Method for Determination of Triple Drugs Combination of Valsartan, Amlodipine and Hydrochlorothiazide in Human Plasma for Bioequivalence Study
Background: Current guidelines for the treatment of hypertension recommend combination therapy, which intends to control blood pressure and enhance cardiovascular protection. Materials and Methods: A sensitive, reliable and selective tandem mass spectrometry (LC-MS/MS) method has been developed for simultaneous quantification of amlodipine (AML), valsartan (VAL) and hydrochlorothiazide (HCTZ) in human plasma. The chromatographic system was equipped with ACE 5 C8 (50 X 2.1 mm) column and utilized a mobile phase composition of 0.5 mM Ammonium Chloride & 0.04% FA-Methanol (45:55% v/v). The method used three internal standards; AML-D4, HCTZ-D2 C13 and VAL-D3 with 10% intra- and inter-day precision, and 6% bias for all the analytes. Results: The assay was found to be linear with R-2 > 0.998, and the limits of quantification for AML, VAL and HCTZ were 0.2, 50.0 and 2.0 ng/mL, respectively. The analytes were found to be stable in plasma samples over short and long term storage. : The developed method is rapid with a run time of 3.5 min and cost-effective since the simple sample preparation method is adopted. This method was successfully applied for the bioequivalence study of AML, VAL, and HCTZ in human plasma after administration of the fixed-dose combination tablet of (10/160/25 mg). Pharmacokinetic parameters (Cmax and AUC0-72) for AML and (Cmax, AUC0-t, AUC0-∞) for VAL and HCTZ were used for bioequivalence assessment. These were determined by noncompartmental analysis of concentration data. Conclusion: The result showed 90% confidence intervals (obtained by ANOVA) which were within the predefined ranges. As a consequence, this method can be successfully applied for measuring and quantifying a large number of samples.
- 25 January 2021
- Published by Elsevier in Current Pharmaceutical Analysis
- Vol. 17 (2) , 241-253
An LC-MS/MS Method for Determination of Triple Drugs Combination of Valsartan, Amlodipine and Hydrochlorothiazide in Human Plasma for Bioequivalence Study
Background: Current guidelines for the treatment of hypertension recommend combination therapy, which intends to control blood pressure and enhance cardiovascular protection. Materials and Methods: A sensitive, reliable and selective tandem mass spectrometry (LC-MS/MS) method has been developed for simultaneous quantification of amlodipine (AML), valsartan (VAL) and hydrochlorothiazide (HCTZ) in human plasma. The chromatographic system was equipped with ACE 5 C8 (50 X 2.1 mm) column and utilized a mobile phase composition of 0.5 mM Ammonium Chloride & 0.04% FA-Methanol (45:55% v/v). The method used three internal standards; AML-D4, HCTZ-D2 C13 and VAL-D3 with 10% intra- and inter-day precision, and 6% bias for all the analytes. Results: The assay was found to be linear with R-2 > 0.998, and the limits of quantification for AML, VAL and HCTZ were 0.2, 50.0 and 2.0 ng/mL, respectively. The analytes were found to be stable in plasma samples over short and long term storage. : The developed method is rapid with a run time of 3.5 min and cost-effective since the simple sample preparation method is adopted. This method was successfully applied for the bioequivalence study of AML, VAL, and HCTZ in human plasma after administration of the fixed-dose combination tablet of (10/160/25 mg). Pharmacokinetic parameters (Cmax and AUC0-72) for AML and (Cmax, AUC0-t, AUC0-∞) for VAL and HCTZ were used for bioequivalence assessment. These were determined by noncompartmental analysis of concentration data. Conclusion: The result showed 90% confidence intervals (obtained by ANOVA) which were within the predefined ranges. As a consequence, this method can be successfully applied for measuring and quantifying a large number of samples.
- 1 February 2017
- Published by Elsevier in Journal of Chromatography B
- Vol. 1043, 33-43
Sorbent, device, matrix and application in microextraction by packed sorbent (MEPS): A review
- 1 February 2017
- Published by Elsevier in Journal of Chromatography B
- Vol. 1043, 33-43
Sorbent, device, matrix and application in microextraction by packed sorbent (MEPS): A review
- 23 September 2015
- Published by Taylor & Francis in Bioanalysis
- Vol. 7 (17) , 2155-2161
Microextraction by Packed Sorbent
Microextraction by packed sorbent (MEPS) is a miniaturized form of SPE. MEPS can handle small sample volumes and be connected on-line with LC or GC without any modifications. In addition, the MEPS sorbent bed is integrated into an injection syringe and can be used for more than 100 extractions. The key aspect of MEPS is that the solvent volume used for the elution of the analytes is of a suitable order of magnitude to be injected directly into GC or LC systems. MEPS has been used in many research fields such as environmental, biological and food analysis. This article gives an overview of the MEPS technique, including fields of application and common formats.
- 23 September 2015
- Published by Taylor & Francis in Bioanalysis
- Vol. 7 (17) , 2155-2161
Microextraction by Packed Sorbent
Microextraction by packed sorbent (MEPS) is a miniaturized form of SPE. MEPS can handle small sample volumes and be connected on-line with LC or GC without any modifications. In addition, the MEPS sorbent bed is integrated into an injection syringe and can be used for more than 100 extractions. The key aspect of MEPS is that the solvent volume used for the elution of the analytes is of a suitable order of magnitude to be injected directly into GC or LC systems. MEPS has been used in many research fields such as environmental, biological and food analysis. This article gives an overview of the MEPS technique, including fields of application and common formats.